Analystreport

Novogen (KZIA) is now covered by Laidlaw. They set a "buy" rating and a $25.00 price target on the stock.

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com